Factors Influencing the Decision to Vaccinate against HPV amongst a Population of Female Health Students.

human papillomavirus invasive cervical cancer student population vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
25 Apr 2022
Historique:
received: 04 03 2022
revised: 13 04 2022
accepted: 21 04 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

In Switzerland, HPV vaccination has been recommended since 2007 for all adolescent girls aged between 11 and 14 years. More than 10 years after the introduction of this recommendation, immunization coverage targets have not been met. Very few studies at a national level describe the reasons for the reluctance of some young women to become vaccinated. The aim of this study is to describe the socio-demographic characteristics of a population of vaccinated and unvaccinated female health students and then to compare the different factors that may have influenced their vaccine choice. Female health students in the French-speaking part of Switzerland, aged between 18 and 31, were invited to participate in the study. A total of 234 female students completed a questionnaire that included questions about their socio-demographic data, sexual behavior and vaccination status. 69% of the participants received at least one dose of the vaccine. Women who had not yet had sex were less likely to be vaccinated than sexually active women (ORa: 0.1, 0.0-0.4, 95% CI), the same as those who did not express an opinion about the importance of vaccination (ORa: 0.1: 0.0-0.6, 95% CI). The main reasons given for refusing vaccination were fear of side effects (26.0%), parental opposition (24.6%) and reluctance of the attending physician (13.6%). The main results of this study highlight a good rate of vaccine coverage in the sample population. Reasons for nonvaccination demonstrate the need to provide information on the vaccine to the target audience, as well as to parents and health professionals.

Sections du résumé

BACKGROUND BACKGROUND
In Switzerland, HPV vaccination has been recommended since 2007 for all adolescent girls aged between 11 and 14 years. More than 10 years after the introduction of this recommendation, immunization coverage targets have not been met. Very few studies at a national level describe the reasons for the reluctance of some young women to become vaccinated. The aim of this study is to describe the socio-demographic characteristics of a population of vaccinated and unvaccinated female health students and then to compare the different factors that may have influenced their vaccine choice.
METHOD METHODS
Female health students in the French-speaking part of Switzerland, aged between 18 and 31, were invited to participate in the study. A total of 234 female students completed a questionnaire that included questions about their socio-demographic data, sexual behavior and vaccination status.
RESULTS RESULTS
69% of the participants received at least one dose of the vaccine. Women who had not yet had sex were less likely to be vaccinated than sexually active women (ORa: 0.1, 0.0-0.4, 95% CI), the same as those who did not express an opinion about the importance of vaccination (ORa: 0.1: 0.0-0.6, 95% CI). The main reasons given for refusing vaccination were fear of side effects (26.0%), parental opposition (24.6%) and reluctance of the attending physician (13.6%).
CONCLUSIONS CONCLUSIONS
The main results of this study highlight a good rate of vaccine coverage in the sample population. Reasons for nonvaccination demonstrate the need to provide information on the vaccine to the target audience, as well as to parents and health professionals.

Identifiants

pubmed: 35632436
pii: vaccines10050680
doi: 10.3390/vaccines10050680
pmc: PMC9144590
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34
pubmed: 16950015
Int J Environ Res Public Health. 2018 Apr 17;15(4):
pubmed: 29673135
Vaccines (Basel). 2020 Jul 16;8(3):
pubmed: 32708759
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 2020 Oct 1;383(14):1340-1348
pubmed: 32997908
Int J Public Health. 2018 Jan;63(1):105-114
pubmed: 29110027
BMC Cancer. 2019 Jan 30;19(1):111
pubmed: 30700274
Int J Environ Res Public Health. 2018 Jul 09;15(7):
pubmed: 29987255
Vaccine. 2012 May 21;30(24):3546-56
pubmed: 22480928
Sex Transm Infect. 2018 Jun;94(4):248-253
pubmed: 29330310
Sex Transm Dis. 2010 Apr;37(4):234-9
pubmed: 19940807
Vaccine. 2010 Nov 3;28(47):7492-500
pubmed: 20851088
BMJ Open. 2016 Jan 27;6(1):e009875
pubmed: 26817639
Int J Public Health. 2012 Jun;57(3):629-32
pubmed: 22371006
J Prim Care Community Health. 2017 Oct;8(4):349-362
pubmed: 29161946
BMJ Open. 2018 May 17;8(5):e021006
pubmed: 29773702
Hum Vaccin Immunother. 2015;11(1):240-4
pubmed: 25483543

Auteurs

Laure Nicolet (L)

Institute of Global Health, Faculty of Medicine, Chemin de Mines 9, 1202 Geneva, Switzerland.

Manuela Viviano (M)

Gynecology Division, Department of Obstetrics and Gynecology, Geneva University Hospitals, Boulevard de la Cluse 30, 1205 Geneva, Switzerland.

Cheryl Dickson (C)

Community Psychiatric Service, Lausanne University Hospital (CHUV), Rue du Bugnon 23, 1011 Lausanne, Switzerland.

Emilien Jeannot (E)

Institute of Global Health, Faculty of Medicine, Chemin de Mines 9, 1202 Geneva, Switzerland.
Community Psychiatric Service, Lausanne University Hospital (CHUV), Rue du Bugnon 23, 1011 Lausanne, Switzerland.

Classifications MeSH